DK3331877T3 - Pyrazolpyrimidinderivat og anvendelser deraf - Google Patents
Pyrazolpyrimidinderivat og anvendelser deraf Download PDFInfo
- Publication number
- DK3331877T3 DK3331877T3 DK16753709.1T DK16753709T DK3331877T3 DK 3331877 T3 DK3331877 T3 DK 3331877T3 DK 16753709 T DK16753709 T DK 16753709T DK 3331877 T3 DK3331877 T3 DK 3331877T3
- Authority
- DK
- Denmark
- Prior art keywords
- pyrimidine derivative
- pyrazole pyrimidine
- pyrazole
- derivative
- pyrimidine
- Prior art date
Links
- KEUDMLLLHGLIGH-UHFFFAOYSA-N 1h-pyrazole;pyrimidine Chemical class C=1C=NNC=1.C1=CN=CN=C1 KEUDMLLLHGLIGH-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200846P | 2015-08-04 | 2015-08-04 | |
| US201562268750P | 2015-12-17 | 2015-12-17 | |
| PCT/IL2016/050852 WO2017021969A1 (en) | 2015-08-04 | 2016-08-04 | Pyrazole pyrimidine derivative and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3331877T3 true DK3331877T3 (da) | 2022-01-03 |
Family
ID=56738143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16753709.1T DK3331877T3 (da) | 2015-08-04 | 2016-08-04 | Pyrazolpyrimidinderivat og anvendelser deraf |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10376511B2 (da) |
| EP (1) | EP3331877B1 (da) |
| JP (1) | JP7083309B2 (da) |
| KR (1) | KR20180043794A (da) |
| CN (1) | CN108137562B (da) |
| AU (2) | AU2016304464B2 (da) |
| CA (1) | CA2994644A1 (da) |
| CY (1) | CY1124898T1 (da) |
| DK (1) | DK3331877T3 (da) |
| ES (1) | ES2901349T3 (da) |
| HK (1) | HK1256535A1 (da) |
| HR (1) | HRP20211949T1 (da) |
| HU (1) | HUE057607T2 (da) |
| IL (1) | IL257282B (da) |
| LT (1) | LT3331877T (da) |
| MX (1) | MX2018001395A (da) |
| PL (1) | PL3331877T3 (da) |
| PT (1) | PT3331877T (da) |
| RS (1) | RS62728B1 (da) |
| RU (1) | RU2735522C2 (da) |
| SI (1) | SI3331877T1 (da) |
| WO (1) | WO2017021969A1 (da) |
| ZA (1) | ZA201800671B (da) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2994644A1 (en) * | 2015-08-04 | 2017-02-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Pyrazole pyrimidine derivative and uses thereof |
| EP3577108B1 (en) | 2017-02-01 | 2021-10-20 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd | N1-(4-(5-(cyclopropylmethyl)-1-methyl-1h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or irak1 inhibitors for treating cancer |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| WO2019155468A1 (en) | 2018-02-08 | 2019-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| TW202110827A (zh) * | 2019-06-03 | 2021-03-16 | 美商拜歐斯瑞克斯公司 | 吡唑化合物之非吸濕性結晶鹽及其醫藥組合物及用途 |
| WO2021000957A1 (zh) * | 2019-07-04 | 2021-01-07 | 北京国鸿生物医药科技有限公司 | 一种杂环化合物、其药物组合物及用途 |
| CR20220066A (es) | 2019-08-14 | 2022-11-28 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 |
| CN115298177A (zh) | 2019-10-11 | 2022-11-04 | 因赛特公司 | 作为cdk2抑制剂的双环胺 |
| US20230047732A1 (en) * | 2020-01-13 | 2023-02-16 | Biotheryx, Inc. | Pyrazolylpyrimidines and use thereof |
| WO2021155050A1 (en) * | 2020-01-29 | 2021-08-05 | Biotheryx, Inc. | Kinase modulators, pharmaceutical compositions, and therapeutic applications |
| TW202304883A (zh) * | 2021-03-24 | 2023-02-01 | 美商拜歐斯瑞克斯公司 | 用於治療惡性實體腫瘤之吡唑基嘧啶 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11752151B2 (en) * | 2021-07-12 | 2023-09-12 | Buddhist Tzu Chi Medical Foundation | Method for enhancing hair growth |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60135676D1 (de) | 2000-12-05 | 2008-10-16 | Vertex Pharma | Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen |
| AU2002308748A1 (en) * | 2001-05-16 | 2002-11-25 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| JP2007530445A (ja) * | 2004-03-30 | 2007-11-01 | 大正製薬株式会社 | ピリミジン誘導体及びその使用に関連する治療方法 |
| JP2007145819A (ja) | 2005-10-28 | 2007-06-14 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| WO2007129195A2 (en) * | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| EP2029578A1 (en) | 2006-05-26 | 2009-03-04 | AstraZeneca AB | 2-carbocycloamino-4-imidaz0lylpyrimidines as agents for the inhbition of cell proliferation |
| CA2707989A1 (en) | 2007-12-07 | 2009-06-11 | Novartis Ag | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
| ES2629690T3 (es) | 2011-11-04 | 2017-08-14 | Jasco Pharmaceuticals, LLC | Inhibidores de aminopirimidina quinasa |
| WO2015048281A1 (en) | 2013-09-27 | 2015-04-02 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CA2994644A1 (en) | 2015-08-04 | 2017-02-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Pyrazole pyrimidine derivative and uses thereof |
| WO2019155468A1 (en) | 2018-02-08 | 2019-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use |
-
2016
- 2016-08-04 CA CA2994644A patent/CA2994644A1/en active Pending
- 2016-08-04 RS RS20211558A patent/RS62728B1/sr unknown
- 2016-08-04 JP JP2018525826A patent/JP7083309B2/ja active Active
- 2016-08-04 RU RU2018107668A patent/RU2735522C2/ru active
- 2016-08-04 US US15/748,536 patent/US10376511B2/en active Active
- 2016-08-04 MX MX2018001395A patent/MX2018001395A/es unknown
- 2016-08-04 AU AU2016304464A patent/AU2016304464B2/en active Active
- 2016-08-04 WO PCT/IL2016/050852 patent/WO2017021969A1/en active Application Filing
- 2016-08-04 SI SI201631426T patent/SI3331877T1/sl unknown
- 2016-08-04 HR HRP20211949TT patent/HRP20211949T1/hr unknown
- 2016-08-04 LT LTEPPCT/IL2016/050852T patent/LT3331877T/lt unknown
- 2016-08-04 EP EP16753709.1A patent/EP3331877B1/en active Active
- 2016-08-04 KR KR1020187006128A patent/KR20180043794A/ko not_active Application Discontinuation
- 2016-08-04 DK DK16753709.1T patent/DK3331877T3/da active
- 2016-08-04 CN CN201680059148.XA patent/CN108137562B/zh active Active
- 2016-08-04 ES ES16753709T patent/ES2901349T3/es active Active
- 2016-08-04 PL PL16753709T patent/PL3331877T3/pl unknown
- 2016-08-04 HU HUE16753709A patent/HUE057607T2/hu unknown
- 2016-08-04 PT PT167537091T patent/PT3331877T/pt unknown
-
2018
- 2018-01-31 ZA ZA2018/00671A patent/ZA201800671B/en unknown
- 2018-01-31 IL IL257282A patent/IL257282B/en active IP Right Grant
- 2018-12-05 HK HK18115603.7A patent/HK1256535A1/zh unknown
-
2019
- 2019-08-12 US US16/538,550 patent/US10960003B2/en active Active
-
2021
- 2021-02-10 AU AU2021200839A patent/AU2021200839A1/en not_active Abandoned
- 2021-03-29 US US17/215,959 patent/US11925641B2/en active Active
- 2021-12-21 CY CY20211101124T patent/CY1124898T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3331877T3 (da) | Pyrazolpyrimidinderivat og anvendelser deraf | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| DK3389658T3 (da) | Glycosidasehæmmere og anvendelser deraf | |
| DK3310371T3 (da) | Glucagon og GLP-1-Co-agonistforbindelser | |
| DK3210977T3 (da) | Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf | |
| IL259150B (en) | Pyrimidine derivative and use thereof | |
| DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
| DK3236991T3 (da) | Fgf21-derivater og anvendelser deraf | |
| DK3269809T3 (da) | MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF | |
| DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
| DK3209773T3 (da) | Prolintolerante tripeptidylpeptidaser og anvendelser deraf | |
| DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
| DK3256479T3 (da) | 4-substituerede benzoxaborolforbindelser og anvendelser deraf | |
| DK3386956T3 (da) | Fumagillolderivater og polymorfer deraf | |
| DE112015003841A5 (de) | Di- und triphosphat-propharmaka | |
| DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf | |
| DK3372589T3 (da) | Pyrimidinderivat | |
| DK3337506T3 (da) | Kombinationer og anvendelser deraf | |
| DK3321279T3 (da) | Exenatidmodificeringsmiddel og anvendelse deraf | |
| DK3180335T3 (da) | Cytokrom-p450-inhibitorer og anvendelser deraf | |
| DK3380465T3 (da) | Diaminopyridinderivativer | |
| DK3280405T3 (da) | Inhibitorer og anvendelser deraf | |
| DK3263133T3 (da) | Pyridinonforbindelse og anvendelse deraf | |
| DK3488521T3 (da) | Køleapparat-kompressorsystem og anvendelse | |
| DK3283571T3 (da) | Klart bindemiddel og anvendelser deraf |